Edition:
United Kingdom

Immunovia AB (publ) (IMMNOV.ST)

IMMNOV.ST on Stockholm Stock Exchange

84.00SEK
13 Dec 2017
Change (% chg)

-1.00kr (-1.18%)
Prev Close
85.00kr
Open
85.00kr
Day's High
86.75kr
Day's Low
82.50kr
Volume
21,316
Avg. Vol
21,423
52-wk High
123.25kr
52-wk Low
82.50kr

Summary

Name Age Since Current Position

Carl Borrebaeck

69 Chairman of the Board

Mats Grahn

Chief Executive Officer

Hans Liljenborg

Chief Financial Officer

Lotta Blomgren

Operations Director

Henrik Winther

Senior Vice President Business Development

Christer Wingren

51 Chief Technology Officer

Rolf Ehrnstrom

Chief Scientific Officer

Laura Chirica

49 Chief Commercial Officer

Linda Mellby

Laboratory Director

Asa Hedin

55 2015 Director

Hans Johansson

63 2016 Director

Ann-Christin Malmborg Hager

52 2015 Director

Ann-Christine Sundell

53 2016 Director

Biographies

Name Description

Carl Borrebaeck

Prof. Carl Borrebaeck serves as Chairman of the Board at Immunovia AB. He has been Director of the Company since 2007. Professor Carl Borrebaeck is a serial entrepreneur, having co-founded Immunovia AB, Senzagen AB, BioInvent International AB (BINV: Stockholm) and Alligator BioScience AB. Prof. Borrebaeck is a 2009 recipient of the AkzoNobel Science Award and was awarded the 2012 Gold Medal from the Royal Academy of Engineering Sciences in recognition of his ground-breaking research regarding biomarkers. In addition, Prof. Borrebaeck is previously the Vice-President of Lund University, Sweden (responsible for its Innovation systems); and currently Director of CREATE Health, a Translational Cancer Center; and chairman of the Department of Immunotechnology. He is Chairman of the Board of Senzagen AB and member of the Board of Alligator Bioscience AB, Clinical Laserthermia Systems AB, WntResearch AB and Ocean Capital AB. Carl Borrebaeck is also Deputy Board Member of Endo Medical AB and partner in Immunova Handelsbolag. Carl Borrebaeck has previously been Board member of LU Innovation System AB, BioInvent International AB, Atlas Therapeutics AB and Medicon Village AB. He has also been Deputy Board member of Ideon Center AB.

Mats Grahn

Mr. Mats Grahn serves as Chief Executive Officer at Immunovia AB. Mats brings more than 25 years experiences in senior leading positions within the life science and diagnostics industry. He contributes with an extensive experience in business and strategic development, marketing, product management, product development and market access. Mats has a track record of leading international commercial operational organizations, restructuring of marketing organizations, integration of acquired companies as well as managing new start-ups. Much of his experience comes from leadership in multinational management teams and organizations in Scandinavia, Europe, USA and Asia. Previous positions include CVP Marketing Dako A/S, VP Product Management GE Healthcare, VP Marketing Amersham Biosciences, VP Laboratory Separations Pharmacia Biotech and VP Prevas Bioinformatics. Mats Grahn holds a Master of Science in Engineering Physics from Lund University, Sweden.

Hans Liljenborg

Mr. Hans Liljenborg serves as Chief Financial Officer at Immunovia AB. Hans Liljenborg has a degree as subject teacher in Business Administration and Mathematics from Lund University, Sweden. Hans has long experience as Financial Manager for growing, global medical technology companies and has been Finance Director at Physio Control Inc, Jolife AB and Finance Manager at Vivoline Medical AB, listed on Nasdaq First North in March 2015. He also operates an own accounting firm. Hans Liljenborg is board member of ADAYS AB and deputy board member in Entreprenorskompetens i Lund AB, IES Interactive Executive Search AB, Gantus Training AB. Hans is also holder of Prosperus and auditor in Solbacka Trading.

Lotta Blomgren

Ms. Lotta Blomgren serves as Operations Director at Immunovia AB (publ). Lotta has more than 30 years’ experience within the life science and diagnostics industry, whereof 15 years in leading positions. She contributes with extensive experience from leading manufacturing, quality control and logistics teams, as well as managing transfer of new products from development to commercial scale. Her track record includes strategic reorganizations of international manufacturing networks, managing people and project portfolios, as well as due diligence of potential acquirement of new companies and Contract Manufacturing (CMO). Previous positions include VP Technical Operations at Euro Diagnostica AB, Head of Supply Chain Bioglan AB, Director Product & Technology Support Ferring A/S, Head of Process Development Ferring AB, cross functional roles within Process Development and Project Management at Astra AB, Kabi Pharmacia AB and ACO AB. Lotta Blomgren holds a M.Sc. in Chemical Engineering from Lund University, Sweden.

Henrik Winther

Mr. Henrik Winther serves as Senior Vice President Business Development at Immunovia AB (publ). Henrik has been at the forefront of companion diagnostics for over 10 years. He brings solid experiences within R&D, business development, regulatory, manufacturing and commercialization of IVD products. From 2006, Henrik was R&D Director at Dako A/S and spearheaded the design responsibility of their most successful product, the HercepTest CDx assay, and later was Head of Dako Business Development and involved in the acquisition of Dako by Agilent Technologies. From 2013-2017, he continued at Agilent in Santa Barbara, CA, as Vice President and General Manager – as well as head of the R&D function – of the Companion Diagnostics Division, and in addition to scaling up the division, increased revenues significantly through fee-for-service collaborations with pharma and CDx-product releases. Henrik holds a DVM and PhD in cell biology and histology from University of Copenhagen. He has earlier worked as an Associate Professor within cell biology, but during the last 17 years focused on cancer diagnostics.

Christer Wingren

Prof. Christer Wingren serves as Chief Technology Officer at Immunovia AB. Professor Wingren is in addition to his role as CTO at Immunovia a lecturer at the Dept. of Immunotechnology within CREATE Health Translational Cancer Center at Lund University, Sweden. Professor Wingren directs a research group working on the development of recombinant antibody microarrays for high-throughput disease proteomics (unlocking biomarker discovery), the Immunovia platform, with a particular focus on oncoproteomics and autoimmunity. The research is conducted in a translational manner, going from the bed-to-bench and back again, with the goal to define serum, plasma, and urine biomarkers for disease diagnosis, prognosis, and classification. In 2014, he was promoted to Professor in Immunotechnology. Prior to joining Immunotechnology in 1999, Dr. Wingren pursued his post-doctoral training in structural biology in the laboratory of Prof. Ian Wilson at the Scripps Research Institute, La Jolla, USA (1997-1999). Dr. Wingren received his Ph.D. in Biochemistry at Lund University in 1997, and a B.Sc. in Chemistry in 1991.

Rolf Ehrnstrom

Mr. Rolf Ehrnstrom serves as Chief Scientific Officer at Immunovia AB. Rolf has more than 30 years of scientific, technical and commercial experience from small, medium and large sized life science and diagnostics companies on the international arena. The last 20 years he served in senior executive management roles. Rolf contributes with an extensive experience in product-, technology- and strategic development in the life science and diagnostics industry. He has a track record of leading large operational organizations (>200 staff), restructuring of large R&D organizations, integration of acquired companies as well as managing rapid growth in new start-ups. Much of his experience comes from leadership in multinational management teams and organizations in Scandinavia, Europe, USA and Asia. His responsibilities have ranged from all technical disciplines within R&D as well as IP, Regulatory, Medical & Clinical Affairs, Scientific Relations/Profiling and External Scientific Collaborations. In recent years a special focus have been in the fields of Personlized Medicine, companion diagnostics and technology innovation where Dako has played a leading role within its field. His important previous positions include: CSO Dako-Agilent, CVP R&D Dako A/S, VP R&D Gyros AB, Science Director Amersham Biosciences, Senior Scientific Advisor Amersham Pharmacia Biotech, Senior Program Manager MicroArrays Amersham-Pharmacia Biotech, Director R&D Molecular Biology Pharmacia Biotech. In the CV are also roles as board member in scientific organization committees and small start-ups. Rolf Ehrnstrom holds a Master of Science in Biochemistry & Biotechnology engineering from Royal Institute of Technology, Stockholm, Sweden.

Laura Chirica

Ms. Laura Chirica serves as Chief Commercial Officer at Immunovia AB. With more than 14 years experiences in leading commercial positions within the life science and diagnostics industry, Laura contributes with an extensive experience in business, organization and strategic development, sales, strategic and tactical marketing, product management and product support. She has a track record of leading and restructuring international sales and marketing organizations, driving business development, champion integration of acquired companies as well as developing branding and market communication platforms. Much of her experience comes from leadership in multinational management teams and organizations in Scandinavia, Europe, USA and Asia. Her previous positions include VP Sales and Marketing Euro Diagnostica AB, Director Purification Technologies Europe Sartorius Stedim, Global Marketing Director Dako A/S, and Global Marketing Program Manager GE Healthcare. Laura Chirica holds a Ph.D. in Biochemistry from Umea University, Sweden, a Master of Science in Biochemistry and a Bachelor of Science in Biotechnology.

Linda Mellby

Ms. Linda Mellby serves as Laboratory Director at Immunovia AB. Linda has more than 10 years experiences of recombinant antibody microarray technology, the Immunovia platform, she has deep knowledge about platform features, technology development as well as clinical applications within oncoproteomics and autoimmunity. She has been one of the key researchers managing the development of the Immunovia antibody microarray platform for disease proteomics, conducting extensive work related to process optimizations, standardizations as well as clinical studies. Linda Mellby received her Ph.D. in Immunotechnology from Dept. of Immunotechnology within CREATE Health Translational Cancer Center, Lund University, in 2010, and a Master of Science in Chemistry Engineering in 2004.

Asa Hedin

Ms. Asa Hedin has served as Director of Immunovia AB since 2015. Asa Hedin has a degree in biophysics from the University of Minnesota and has a bachelor’s degree in physics from Gustavus Adolphus College. Asa Hedin also has a Diploma Pro Board work, M Berglund Board value. Asa Hedin is Chairman and CEO of ASH&Partners AB and Board Member of E. Ohman J: or Fonder AB, Nolato Aktiebolag, The Swedish Space Corporation, CellaVision AB and Tobii AB. Asa Hedin has previously been Executive Vice President (EVP) of Corporate Strategy and member of Group Management of Elekta Instrument AB. She has also been Senior Vice President, Head of Corporate Strategic Development of Gambro AB, Board member of Rodebjer Form AB and MedCap AB (publ). Asa Hedin has also been Deputy Member of the Board of Kihlborg Film Company Limited.

Hans Johansson

Mr. Hans Johansson has been Director of Immunovia AB (publ) since December 9, 2016. Hans Johansson has excessive experience and a wide network from his previous positions such as VP, Head of Companion Diagnostics at ThermoFisher Inc Speciality Diagnostics Group (with a turnover of USD 3 billion). Hans Johansson was also a former VP of Global Marketing and Commercial Development within the same company but at the ImmunoDiagnostics division and earlier VP, Head of the Laboratory Business Unit at Pharmacia Biotechnology. Hans has also been an active entrepreneur as CEO/Board member in the life science sector. Altogether, he has 30 years of experience from global business development and commercialization of biotechnical and diagnostic innovations. He holds M.Sc. in Chemical Engineering. He serves as Board member of Uppsala Innovation Centre AB, Single Technologies AB earlier also board member at AffiBody AB, Chairman of the BoD for AroCell AB and member of the nomination committee at IscoNova AB.

Ann-Christin Malmborg Hager

Dr. Ann-Christin Malmborg Hager, Ph.D. has served as Director of Immunovia AB since 2015. Ann-Christin Malmborg Hager has a Ph.D. in immunoassay technology. Ann-Christin Malmborg Hager has commercial experience from current and previous positions as CEO of SenzaGen AB, she has previously been CEO of several start-up companies including Cantargia, Diaprost, XImmune and Investment Director. In addition, Ann-Christin Malmborg Hager has experience in Business Development. Ann-Christin Malmborg Hager is Chief Executive Officer for SenzaGen AB. She is a Board member of Diaprost AB, Hager Consulting, Avena Partners AB and bulb Intelligence AB. Ann-Christin Malmborg Hager has previously been a Board member of WC Likvid AB, Cantargia AB and XImmune AB.

Ann-Christine Sundell

Ms. Ann-Christine Sundell has been Director of Immunovia AB (publ) since December 9, 2016. She has 30 years of experience from the medical device industry, she has held various global positions. For 10 years she served as president for Genetic Screening, one of five strategic business areas with over 1500 employees worldwide within PerkinElmer, one of the largest Life Science companies. Ann-Christine has strategic and operational experience from areas where Immunovia is active such as Sales & Marketing, R&D, production, quality and compliance. She holds M.Sc. in Biochemistry. She serves as Chairman of the Board of Serres Oy and member of the Board of Oy Medix, Minerva Foundation for Medical Research, Raisio Oyj, Ledil Oy, Zymonostics ApS and Revenio Group Oyj.